News | August 26, 2025
Remedium Lifecare charts 4X growth strategy
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Akums invested Rs. 272 crore in capital expenditure during FY25
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Strengthening capabilities in Peptide Therapeutics and CDMO services
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA
Subscribe To Our Newsletter & Stay Updated
